504 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
Download search resultsDownload the search results for:
multiple myeloma | Open Studies | multiple myeloma (504 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: desipramine hydrochloride;   Biological: filgrastim;   Other: laboratory biomarker analysis
2 Recruiting Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dalteparin;   Drug: lenalidomide;   Drug: dexamethasone;   Other: laboratory biomarker analysis
3 Not yet recruiting Imaging Studies and the Development of Multiple Myeloma
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide
4 Recruiting Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
5 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
6 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
7 Recruiting 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
8 Not yet recruiting Combination Study of Pomalidomide, Marizomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
9 Recruiting Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
10 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
11 Recruiting Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
12 Recruiting Ixazomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: quality-of-life assessment
13 Recruiting A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
14 Recruiting Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Thrombocytopenia
Intervention: Biological: romiplostim
15 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
16 Recruiting Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation;   Drug: bortezomib;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Genetic: polymerase chain reaction
17 Not yet recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
18 Unknown  High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
19 Recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
20 Recruiting S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years